Cardiac science inc. : the irvine company said...
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Loading...
Cardiac Science Inc.: The Irvine company said Thursday that it has received approval from the Food and Drug Administration to start the second phase of human clinical trials of its
non-surgical defibrillator device for high-risk heart patients. The trials are expected to begin in the next quarter at the Arizona Heart Institute in Phoenix. Phase I testing was completed
at UC Irvine Medical Center, Montefiore Medical Center in New York, and the Arizona Heart Institute in Phoenix. MORE TO READ